Pharmacological inhibition with the ataxia telangiectasia and Rad3-relevant protein serine/threonine kinase (ATR; generally known as FRAP-relevant protein (FRP1)) has emerged as being a promising strategy for cancer treatment that exploits artificial lethal interactions with proteins associated with DNA harm repair, overcomes resistance to other th